Association of Elevated Yes-Associated Protein Expression with Gastric Cancer and Its Clinicopathological Features: A Meta-Analysis

Qian Peng1*, Ting Yuan2*, Xingmei Duan2*, Jianyou Shi2, Lan Bai2, Jiying Yu2#, Lei Zhong2#

1Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
2Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

Email: ’yujiying@163.com, ’zhl7235301@163.com

Abstract

Objectives: To evaluate the difference of YAP-positive expression between GC and adjacent tissues, as well as the association of elevated YAP expression with clinicopathological features of GC. Methods: PubMed, Embase, Web of Science databases and the Chinese National Knowledge Infrastructure (CNKI) were searched from inception up to December 2018. The pooled ORs and corresponding 95% CIs were used to assess the strength of association. The heterogeneity among eligible studies was evaluated by the Q-test and I² values. The sensitivity analysis was performed by sequential omission of individual studies. Moreover, Begg’s test and Egger’s test were used to evaluate publication bias. Results: A total of 2229 patients from 16 studies were included in this meta-analysis. The results showed that positive YAP expression was closely correlated with GC but not adjacent non-tumor tissue (OR = 8.08, 95% CI = 4.41 - 14.80). Additionally, YAP overexpression was found to be associated with more advanced TNM stage (OR = 2.68, 95% CI = 1.61 - 4.48), deeper invasion depth (OR = 2.05, 95% CI = 1.32 - 3.19), and lymph node metastasis (OR = 1.95, 95% CI = 1.29 - 2.96). No significant correlation was observed between YAP overexpression and degree of differentiation (OR = 1.17, 95% CI = 0.63 - 2.16), as well as gender of patients (OR = 1.12, 95% CI = 0.91 - 1.37) or tumor size (OR = 1.11, 95% CI = 0.82 - 1.49) of gastric cancer. Conclusions: This meta-analysis demonstrated that YAP might be a promising diagnostic marker and even a therapeutic target for gastric cancer.

Keywords

Yes-Associated Protein, Gastric Cancer, Clinicopathological Feature, Meta-Analysis

*These authors contributed equally to this work.
1. Introduction

Gastric cancer (GC) is one of the most common malignant tumors in the digestive system. It has become the third leading cause of cancer death worldwide. Over 70% of GC cases occur in developing countries, and roughly half of the world’s total occurs in eastern Asia (chiefly in China) [1]. Most GC patients present with advanced tumor due to the inconspicuous symptoms of early onset GC and the limited diagnostic conditions, making the sufferers lose the optimal opportunity for radical cure [2]. For these patients, systemic treatments, such as chemotherapy, are the main treatment option. Although great progress has been made for advanced GC chemotherapy in recent years, mortality is still unacceptably high. Therefore, searching for ideal diagnostic biomarkers and novel therapeutic targets remains critical for the treatment of GC.

Hippo signaling pathway is an evolutionarily conserved regulator for organ size control and tissue growth. Accumulating literature suggests that dysregulation of Hippo pathway leads to proliferation and anti-apoptosis associated with increased cancer risk [3] [4] [5]. As a pivotal downstream effector of Hippo signal cascade, Yes-associated protein (YAP) was considered as an oncoprotein, and its overexpression and accumulation in the nucleus were closely related to the poor clinical outcomes of various tumors including gastric cancer [6] [7]. Moreover, YAP was even reported as a potential target for GC therapy [8]. Nevertheless, the published clinical studies showed the data were still controversial, and the opposite role of YAP in GC was also reported [9]. Therefore, we conducted this meta-analysis to comprehensively assess the relationship between YAP overexpression and gastric cancer.

2. Methods

2.1. Search Strategy

We performed a systematic literature search in PubMed, Embase, Web of Science databases and the Chinese National Knowledge Infrastructure (CNKI) from inception up to December 2018. Relevant studies were identified using a combination of the following terms: “YAP” or “Yes-associated protein” or “Yes protein” or “Hippo” and “gastric cancer” or “gastric carcinoma” or “gastric neoplasm” or “stomach cancer” or “GC”. To availably identify relevant studies, we also manually searched for references cited in the eligible articles. When two studies had partial overlaps, both studies should be considered.

2.2. Inclusion and Exclusion Criteria

The eligible literature in this study fulfill the following inclusion criteria: 1) patients were diagnosed as gastric cancer; 2) YAP expression was quantified by immunohistochemistry or other adequate methods; 3) sufferers were categorized into high YAP (or YAP-positive) and low YAP (or YAP-negative) groups; 4) the association between YAP expression and clinicopathological features was described, or YAP expression in human tumor and adjacent tissues was detected;
5) the search was restricted to human studies published in English or Chinese. Studies were excluded if they met any of the following exclusion criteria: a) reviews, case reports, comments, conference abstracts, letters, or laboratory studies; b) published in a language other than English or Chinese; c) insufficient data available to estimate the association.

2.3. Data Extraction

Required data were extracted by two investigators independently based on the inclusion criteria listed above. Any discrepancies in data extraction were evaluated by discussion to reach a consensus. The extracted data included the first author’s name, year of publication, country of origin, distribution of gender and age in patients, number of patients, staining location, method of detection, YAP expression in gastric cancer and adjacent normal tissue, and clinicopathological features.

2.4. Assessment of Study Quality

Two investigators independently evaluated the quality of each study according to Newcastle-Ottawa Scale (NOS) [10]. The NOS includes three parameters of quality for studies: selection of the study population, comparability of subjects, and exposure assessment, with scores ranging from 0 to 9 (Additional file 1: Table S1). NOS scores > 5 was considered as high-quality studies.

2.5. Statistical Analysis

We implemented the meta-analysis based on the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Checklist (Additional file 2: Table S2). The odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs) were used to assess the association between YAP expression and gastric cancer or the clinicopathological features of gastric cancer. The heterogeneity among eligible studies was evaluated by the Q-test. $P$-value < 0.1 indicated that the heterogeneity was significant. $I^2$ values were also calculated to quantify the heterogeneity: $I^2 < 25\%$, $25\% < I^2 < 50\%$, $50\% < I^2 < 75\%$, and $I^2 > 75\%$, indicated no heterogeneity, moderate heterogeneity, large heterogeneity, and extreme heterogeneity, respectively. When $P$-value > 0.1 and $I^2 < 25\%$, the heterogeneity was considered not significant, and then the pooled OR and 95% CI were assessed by the fixed-effects model; otherwise, the random-effects model was performed [11]. The sensitivity analysis was carried out by sequential omission of individual studies to test the stability of meta-analysis results. Moreover, Begg’s test and Egger’s test were used to evaluate the publication bias; $P$-value < 0.05 indicated the presence of publication bias. All statistical analyses were performed using the software STATA version 12.0 (Stata Corporation, College Station, TX, USA).

3. Results

3.1. Study Characteristics

The flow chart of the study selection process was presented in Figure 1. A total
According to the inclusion and exclusion criteria, data from 16 studies including 2229 patients were included in this meta-analysis [9] [12]-[26]. As shown in Table 1, the eligible studies were published between 2009 and 2018, and sample sizes ranged from 53 to 302. 12 studies (75.00%) reported on Chinese, 3 studies (18.75%) on Koreans, and only 1 study (6.25%) on Japanese. YAP expression was detected by immunohistochemistry in all eligible studies, among them, formalin-fixed and paraffin-embedded (FFPE) samples were used for immunohistochemical staining in 8 studies, while the other 8 studies used tissue microarray (TMA). Of the eligible publications, 13 studies reported nuclear and cytoplasmic staining of YAP (overall YAP expression), and 3 studies detected YAP expression only by nuclear staining. Additionally, the quality of each eligible study was assessed according to the NOS, and all articles were of high quality (NOS score > 5).

3.2. The Difference of YAP-Positive Expression between GC and Adjacent Tissues

YAP expression in GC and adjacent non-tumor tissues was detected simultaneously in 8 studies [12] [15] [16] [17] [21] [22] [24] [26]. As depicted in Table 2, the eight studies included 925 GC samples (case) and 728 paracancerous samples (control). YAP-positive rate in GC was much higher than that in normal tissues (OR = 8.08, 95% CI = 4.41 - 14.80). Moreover, the results of meta-analysis showed that 95% confidence intervals of combined study, as well as each independent
Table 1. Characteristics of the studies included in the meta-analysis.

| Author | Year | Country | Gender (male/female) | Age (year) | Patient number (negative/positive) | Staining location | Method of detection | NOS | Ref. |
|--------|------|---------|----------------------|------------|-----------------------------------|------------------|--------------------|-----|------|
| Da CL  | 2009 | China   | 66/32                | ≥60, 54 <60, 44 | 98 (51/47)                       | YAP expression   | TMA                | 7   | [12] |
| Song M | 2012 | South Korea | 140/83         | ≥65, 68 <65, 155 | 223 (162/61)                     | YAP nuclear expression | FFPE tissues | 6   | [13] |
| Zhang J| 2012 | China   | 39/14                | ≥70, 20 <70, 33 | 53 (33/20)                       | YAP expression   | TMA                | 6   | [14] |
| Luo H  | 2013 | China   | 40/16                | Median: 66.1 ± 3.7, (range: 60 - 73) | 56 (16/40)            | YAP expression   | FFPE tissues | 7   | [15] |
| Hu X   | 2014 | China   | 64/150               | >61, 103 ≤61, 111 | 214 (67/147)                     | YAP expression   | TMA                | 7   | [16] |
| Suh JH | 2015 | South Korea | -                  | Median: 64.6 (range: 39 - 88) | 116 (66/50)           | YAP expression   | TMA                | 7   | [9]  |
| Huang S| 2017 | China   | 87/33                | >57.5, 60 <57.5, 60 | 120 (16/104)            | YAP nuclear expression | FFPE tissues | 7   | [17] |
| Sun D  | 2017 | China   | 216/86               | >55, 192 ≤55, 110 | 302 (64/238)         | YAP expression   | TMA                | 7   | [18] |
| Nambara S | 2017 | Japan   | 68/33                | ≥65, 54 <65, 47 | 101 (35/66)                     | YAP expression   | FFPE tissues | 6   | [19] |
| Hong SA| 2017 | South Korea | 118/48         | ≥62.5, 83 <62.5, 83 | 166 (85/81)           | YAP expression   | TMA                | 6   | [20] |
| Yu B   | 2017 | China   | 73/25                | ≥60, 68 <60, 30 | 98 (22/76)                      | YAP nuclear expression | TMA       | 7   | [21] |
| Fan JH | 2017 | China   | 53/34                | ≥58, 52 <58, 35 | 87 (50/37)                     | YAP expression   | FFPE tissues | 7   | [22] |
| Fu Y   | 2018 | China   | 84/76                | Median: 58 ± 3 | 160 (55/105)                   | YAP expression   | FFPE tissues | 6   | [23] |
| Bao SS | 2018 | China   | 82/35                | ≥60, 66 <60, 51 | 117 (28/89)                   | YAP expression   | FFPE tissues | 7   | [24] |
| Han XY | 2018 | China   | 129/54               | ≥60, 107 <60, 76 | 183 (46/137)                   | YAP expression   | FFPE tissues | 6   | [25] |
| Xiao L | 2018 | China   | 99/36                | >60, 48 ≤60, 87 | 135 (68/67)                    | YAP expression   | TMA                | 7   | [26] |

Abbreviations: YAP, Yes-associated protein; TMA, tissue microarray; FFPE, formalin-fixed and paraffin-embedded; NOS, Newcastle-Ottawa Scale.

Table 2. YAP expression in gastric cancer and adjacent non-tumor tissue.

| Author | Year | Case  | Control | Case  | Control |
|--------|------|-------|---------|-------|---------|
|        |      | YAP (+)| YAP (-) | YAP (+)| YAP (-) |
| Da CL  | 2009 | 98    | 98      | 47    | 51      | 13     | 85     |
| Luo H  | 2013 | 56    | 56      | 40    | 16      | 8      | 48     |
| Hu X   | 2014 | 214   | 167     | 147   | 67      | 32     | 135    |
| Huang S| 2017 | 120   | 30      | 104   | 16      | 20     | 10     |
| Yu B   | 2017 | 98    | 98      | 22    | 76      | 0      | 98     |
| Fan JH | 2017 | 87    | 27      | 50    | 37      | 5      | 22     |
| Bao SS | 2018 | 117   | 117     | 89    | 28      | 12     | 105    |
| Xiao L | 2018 | 135   | 135     | 67    | 68      | 33     | 102    |
study, exceeded “1”, indicating that positive YAP expression was correlated with gastric cancer but not adjacent non-tumor tissue (Figure 2(a)).

3.3. Association of YAP Overexpression with GC Clinicopathological Features

The main results of meta-analysis and heterogeneity test for the association study of YAP overexpression with gastric cancer clinicopathological features were summarised in Table 3. The elevated YAP expression was correlated with more advanced TNM stage (OR = 2.68, 95% CI = 1.61 - 4.48) (Figure 3(a)), deeper invasion depth (OR = 2.05, 95% CI = 1.32 - 3.19) (Figure 3(b)), and lymph node metastasis (OR = 1.95, 95% CI = 1.29 - 2.96) (Figure 3(c)) in gastric cancer. Moreover, no significant correlation was observed between YAP overexpression and degree of differentiation (OR = 1.17, 95% CI = 0.63 - 2.16) (Figure 3(d)), as well as gender of patients (OR = 1.12, 95% CI = 0.91 - 1.37) (Figure S1(a)) or tumor size (OR = 1.11, 95% CI = 0.82-1.49) (Figure S1(b)) of gastric cancer.

Figure 2. The difference of YAP-positive expression between gastric cancer and adjacent tissues. (a) Forest plot for the association between YAP-positive expression and gastric cancer; (b) Sensitivity analysis for the association between YAP-positive expression and gastric cancer.

Table 3. The correlation of YAP overexpression with GC clinicopathological features.

| Variable                  | No. studies | Model   | OR (95% CI)       | Heterogeneity | Begg's test | Egger's test |
|---------------------------|-------------|---------|-------------------|---------------|-------------|--------------|
|                           |             |         |                   | I² (%)        | P-value (Q-test) | P-value (Q-test) |
| Gender<sup>a</sup>        | 14          | Fixed   | 1.12 (0.91, 1.37) | 12.9          | 0.312       | 0.661        | 0.285        |
| Tumor size<sup>b</sup>    | 8           | Fixed   | 1.11 (0.82, 1.49) | 39.6          | 0.115       | 0.902        | 0.139        |
| TNM stage<sup>c</sup>     | 12          | Random  | 2.68 (1.61, 4.48) | 78.4          | 0.000       | 0.086        | 0.160        |
| Invasion depth<sup>d</sup>| 8           | Random  | 2.05 (1.32, 3.19) | 54.0          | 0.033       | 0.174        | 0.500        |
| Lymph node metastasis<sup>e</sup> | 14          | Random  | 1.95 (1.29, 2.96) | 71.8          | 0.000       | 0.443        | 0.847        |
| Degree of differentiation<sup>f</sup> | 11          | Random  | 1.17 (0.63, 2.16) | 82.3          | 0.000       | 0.436        | 0.521        |

Notes: <sup>a</sup>Male/female; <sup>b</sup>5 cm≥/5 cm; <sup>c</sup>III + IV/I + II; <sup>d</sup>T3 + T4/T1 + T2; <sup>e</sup>Yes/No; <sup>f</sup>Low differentiation/middle and high differentiation.
Figure 3. The association of elevated YAP expression with clinicopathological features of GC. Forest plots for the association between elevated YAP expression and (a) TNM stage, (b) invasion depth, (c) lymph node metastasis, or (d) degree of differentiation in GC.

3.4. Sensitivity Analysis

We conducted sensitivity analysis by sequential omission of individual studies to probe the change in the odds ratio and 95% confidence interval of meta-analysis. As shown in Figure 2(b), Figures 4(a)-(d) and Figure S1(c) & Figure S1(d), no significant difference was observed when any of the studies was excluded in all correlation assessments, indicating the reliability and stability of the meta-analysis.

3.5. Publication Bias

Begg–Mazumdar adjusted rank correlation test and Egger’s regression test were performed to assess the publication bias. The results showed that the shape of Begg’s funnel plots appeared to be symmetrical (data not shown). Meanwhile, the $P$-values were all greater than 0.05 in both Begg’s test and Egger’s test (Table 3). These results suggested the absence of significant publication bias in the overall meta-analysis.
4. Discussion

Gastric cancer is characteristic of poor prognosis and high death rate, and there is still a great need to identify diagnostic markers as well as develop novel therapeutic strategies for GC therapy. Hippo pathway regulates tissue growth and organ size via YAP-TEAD complex. Inactivation of Hippo cascade leads to the elevated expression and nucleus accumulation of YAP, which is significantly associated with poor clinical outcomes of most cancers. Therefore, Hippo cascade acts as a tumor suppressor pathway, and YAP is considered to be an oncoprotein in multiple cancers including GC. There are many published clinical data supporting this conclusion. Zhang reported that YAP was strongly expressed in GC, and knockdown of YAP could inhibit the proliferation and metastasis of GC cells [27]. The similar results could also be observed in the study of Zhou and his colleagues [28]. Moreover, Yan showed that YAP acted as a tumor promoter in gastric cancer, and involved in the survival and migration of GC cells through the activation of the SIRT1/Mfn2/mitochondrial autophagy axis [29]. However, there are still inconsistent results published. Suh and colleagues supported that YAP functioned as a tumor suppressor in GC [9]. Zhang also indicated that there
was no significant correlation between YAP expression and clinicopathological characteristics in GC, and YAP was not a potential marker for diagnosis or prognosis of GC [14]. In this account, a meta-analysis including 16 studies was performed to comprehensively evaluate the relevance of elevated YAP expression with GC and its pathological parameters. The results of pooled data showed a significant correlation between positive YAP expression and GC, but not adjacent non-tumor tissue. Furthermore, the elevated YAP expression in GC was closely related to more advanced TNM stage, deeper invasion depth and lymph node metastasis.

The heterogeneity and several limitations of this meta-analysis should be acknowledged. First, all of the eligible studies in this meta-analysis were carried out in Asian population, therefore, it might be insufficient to provide support for other ethnic groups. Second, the evaluation criteria of positive YAP expression differed among included studies, which might influence the results of pooled data and contribute to the heterogeneity. Third, the data we extracted contain both YAP nuclear staining and overall YAP expression, the difference in staining location is also a potential heterogeneous source due to the expression characteristics of YAP in different cell states.

In conclusion, this meta-analysis demonstrated that YAP-positive expression in gastric cancer was significantly higher than that in adjacent non-tumor tissues. Additionally, the overexpression of YAP was closely correlated with more advanced TNM stage, deeper invasion depth and lymph node metastasis. Therefore, YAP may be a promising diagnostic marker and even a therapeutic target for GC. However, the results of this study should be interpreted cautiously due to the existence of heterogeneity and limitations. Hence, well-designed prospective studies based on larger sample sizes, as well as the corresponding basic research are still warranted to validate the present findings.

**Acknowledgements**

This work was supported by the Fundamental Research Funds of Science & Technology Department of Sichuan Province (2017YSKY0001), the Scientific Research Subject of Health and Family Planning Commission of Sichuan Province (17PJ582), and the Applied Basic Research Fund of Science & Technology Department of Sichuan Province (2018JY0652).

**Conflicts of Interest**

The authors declare no conflicts of interest regarding the publication of this paper.

**References**

[1] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. *International Journal of Cancer*, 136, E359-E386. [https://doi.org/10.1002/ijc.29210](https://doi.org/10.1002/ijc.29210)
[2] Venerito, M., Link, A., Rokkas, T. and Malfertheiner, P. (2016) Gastric Cancer—Clinical and Epidemiological Aspects. *Helicobacter*, 21, 39-44. https://doi.org/10.1111/hel.12339

[3] Staley, B.K. and Irvine, K.D. (2012) Hippo Signaling in Drosophila: Recent Advances and Insights. *Developmental Dynamics*, 241, 3-15. https://doi.org/10.1002/dvdy.22723

[4] Johnson, R. and Halder, G. (2014) The Two Faces of Hippo: Targeting the Hippo Pathway for Regenerative Medicine and Cancer Treatment. *Nature Reviews Drug Discovery*, 13, 63-79. https://doi.org/10.1038/nrd4161

[5] Mo, J.S., Park, H.W. and Guan, K.L. (2014) The Hippo Signaling Pathway in Stem Cell Biology and Cancer. *Embo Reports*, 15, 642-656. https://doi.org/10.15252/embr.201438638

[6] Kang, W., Tong, J.H., Chan, A.W., Lee, T.L., Lung, R.W., Leung, P.P., So, K.K., Wu, K., Fan, D., Yu, J., Sung, J.J. and To, K.F. (2011) Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis. *Clinical Cancer Research*, 17, 2130-2139. https://doi.org/10.1158/1078-0432.CCR-10-2467

[7] Steinhardt, A.A., Gayyed, M.F., Klein, A.P., Dong, J., Maitra, A., Pan, D., Montgomery, E.A. and Anders, R.A. (2008) Expression of Yes-Associated Protein in Common Solid Tumors. *Human Pathology*, 39, 1582-1589. https://doi.org/10.1016/j.humpath.2008.04.012

[8] Zhou, Z., Zhu, J.S., Xu, Z.P. and Zhang, Q. (2011) Lentiviral Vector-Mediated siRNA Knockdown of the YAP Gene Inhibits Growth and Induces Apoptosis in the SGC7901 Gastric Cancer Cell Line. *Molecular Medicine Reports*, 4, 1075-1082. https://doi.org/10.3892/mmr.2011.543

[9] Suh, J.H., Won, K.Y., Kim, G.Y., Bae, G.E., Lim, S.J., Sung, J.Y., Park, Y.K., Kim, Y.W. and Lee, J. (2015) Expression of Tumoral FOXP3 in Gastric Adenocarcinoma Is Associated with Favorable Clinicopathological Variables and Related with Hippo Pathway. *International Journal of Clinical and Experimental Pathology*, 8, 14608-14618.

[10] Stang, A. (2010) Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses. *European Journal of Epidemiology*, 25, 603-605. https://doi.org/10.1007/s10654-010-9491-z

[11] Higgins, J.P., Thompson, S.G., Deeks, J.J. and Altman, D.G. (2003) Measuring Inconsistency in Meta-Analyses. *BMJ*, 327, 557-560. https://doi.org/10.1136/bmj.327.7414.557

[12] Da, C.L., Xin, Y., Zhao, J. and Luo, X.D. (2009) Significance and Relationship between Yes-Associated Protein and Survivin Expression in Gastric Carcinoma and Precancerous Lesions. *World Journal of Gastroenterology*, 15, 4055-4061. https://doi.org/10.3748/wjg.15.4055

[13] Song, M., Cheong, J.H., Kim, H., Noh, S.H. and Kim, H. (2012) Nuclear Expression of Yes-Associated Protein 1 Correlates with Poor Prognosis in Intestinal Type Gastric Cancer. *Anticancer Research*, 32, 3827-3834.

[14] Zhang, J., Yang, Y.C., Zhu, J.S., Zhou, Z. and Chen, W.X. (2012) Clinicopathologic Characteristics of YES-Associated Protein 1 Overexpression and Its Relationship to Tumor Biomarkers in Gastric Cancer. *International Journal of Immunopathology and Pharmacology*, 25, 977-987. https://doi.org/10.1177/039463201202500415

[15] Luo, H. (2013) Expression of YAP Protein in Elderly Patients with Gastric Cancer and Its Effect on Prognosis. *Chinese Journal of Gerontology*, 33, 6140-6141.

[16] Hu, X., Xin, Y., Xiao, Y. and Zhao, J. (2014) Overexpression of YAP1 Is Correlated
with Progression, Metastasis and Poor Prognosis in Patients with Gastric Carcinoma. *Pathology & Oncology Research, 20*, 805-811. https://doi.org/10.1007/s12253-014-9757-y

[17] Huang, S., Zhu, L., Cao, Y., Li, L., Xie, Y., Deng, J. and Xiong, J. (2017) Significant Association of YAP1 and HSPC111 Proteins with Poor Prognosis in Chinese Gastric Cancer Patients. *Oncotarget, 8*, 80303-80314. https://doi.org/10.18632/oncotarget.17932

[18] Sun, D., Li, X., He, Y., Li, W., Wang, Y., Wang, H., Jiang, S. and Xin, Y. (2016) YAP1 Enhances Cell Proliferation, Migration, and Invasion of Gastric Cancer *in Vitro and in Vivo*. *Oncotarget, 7*, 81062-81076. https://doi.org/10.18632/oncotarget.13188

[19] Nambara, S., Masuda, T., Nishio, M., Kuramitsu, S., Tobo, T., Ogawa, Y., Hu, Q., Iguchi, T., Kuroda, Y., Ito, S., Eguchi, H., Sugimachi, K., Saeke, H., Oki, E., Maehara, Y., Suzuki, A. and Mimori, K. (2017) Antitumor Effects of the Antiparasitic Agent Ivermectin via Inhibition of Yes-Associated Protein 1 Expression in Gastric Cancer. *Oncotarget, 8*, 107666-107677. https://doi.org/10.18632/oncotarget.22587

[20] Hong, S.A., Son, M.W., Cho, J., Jang, S.H., Lee, H.J., Lee, J.H., Cho, H.D., Oh, M.H. and Lee, M.S. (2017) Low Angiomotin-p130 with Concomitant High Yes-Associated Protein 1 Expression Is Associated with Adverse Prognosis of Advanced Gastric Cancer. *APMIS, 125*, 996-1006. https://doi.org/10.1111/apm.12750

[21] Yu, B., Chen, H., Wang, W., Yin, Y., Xiao, L., Wang, H., Li, Y. and Chen, Y. (2017) Expression of Yes-Associated Protein in Gastric Adenocarcinoma and Its Clinical Significance. *Oncology Progress, 15*, 435-439.

[22] Fan, J.H. (2017) Clinicopathologic Significance and Correlation of YAP, TAZ and β-Catenin Expression in Gastric Cancer. Shanxi Medical University, Taiyuan, 12-14.

[23] Fu, Y., Lü, Z.W., Liu, X.Y., Wu, J.W. and Guo, Y.Q. (2018) Expressions of FAT4, CUL4 and YAP in Gastric Cancer and Their Clinical Significance. *China Journal of Modern Medicine, 28*, 26-31.

[24] Bao, S.S. and Chen, G.R. (2018) Relationship between the Expression of YAP and VGLL4 Protein and the Invasion and Metastasis of Gastric Cancer. *Journal of Mathematical Medicine, 31*, 974-976.

[25] Han, X.Y., Sun, J., Li, Y.Y., Li, X.Q., Ju, Y.B. and Zhang, Z.G. (2018) Expression of YAP and VGLL4 in Gastric Carcinoma and Its Effects on the Invasion and Metastasis. *Modern Oncology, 26*, 237-240.

[26] Xiao, L., Huang, C.H., Yuan, W.J., Chen, J.X., Luo, Q.Q. and Chen, Z.H. (2018) Expressions of YAP1, E-Cadherin and N-Cadherin in Gastric Cancer Tissue and Their Clinical Significance. *Chinese Journal of General Surgery, 27*, 442-448.

[27] Zhang, J., Xu, Z.P., Yang, Y.C., Zhu, J.S., Zhou, Z. and Chen, W.X. (2012) Expression of Yes-Associated Protein in Gastric Adenocarcinoma and Inhibitory Effects of Its Knockdown on Gastric Cancer Cell Proliferation and Metastasis. *International Journal of Immunopathology and Pharmacology, 25*, 583-590. https://doi.org/10.1177/039463201202500304

[28] Zhou, Z., Zhu, J.S., Gao, C.P., Li, L.P., Zhou, C., Wang, H. and Liu, X.G. (2016) siRNA Targeting YAP Gene Inhibits Gastric Carcinoma Growth and Tumor Metastasis in SCID Mice. *Oncology Letters, 11*, 2806-2814. https://doi.org/10.3892/ol.2016.4319

[29] Yan, H., Qiu, C., Sun, W., Gu, M., Xiao, F., Zou, J. and Zhang, L. (2018) Yap Regulates Gastric Cancer Survival and Migration via SIRT1/Mfn2/Mitophagy. *Oncology Reports, 39*, 1671-1681. https://doi.org/10.3892/or.2018.6252
### Appendix

**Table S1.** Newcastle-ottawa quality assessment scale.

| Study | Selection | Comparability | Exposure | Score |
|-------|-----------|---------------|----------|-------|
|       | Is the case definition adequate? | Representativeness of the cases | Selection of controls | Definition of controls | Comparability of cases and controls on the basis of the design or analysis | Ascertainment of exposure | Same method of ascertainment for cases and controls | Non-Response rate |
| a) Yes, with independent validation |☆ |☆ |☆ |☆ |☆ |☆ |☆ |7 |
| b) Yes, e.g. record linkage or based on self reports |☆ |☆ |☆ |☆ |☆ |☆ |☆ |6 |
| c) No description |☆ |☆ |☆ |☆ |☆ |☆ |☆ |7 |
| Song M |☆ |☆ |☆ |☆ |☆ |☆ |☆ |6 |
| Zhang J |☆ |☆ |☆ |☆ |☆ |☆ |☆ |6 |
| Luo H |☆ |☆ |☆ |☆ |☆ |☆ |☆ |7 |
| Hu X |☆ |☆ |☆ |☆ |☆ |☆ |☆ |7 |
| Suh JH |☆ |☆ |☆ |☆ |☆ |☆ |☆ |7 |
| Huang S |☆ |☆ |☆ |☆ |☆ |☆ |☆ |7 |
| Sun D |☆ |☆ |☆ |☆ |☆ |☆ |☆ |7 |
| Nambara S |☆ |☆ |☆ |☆ |☆ |☆ |☆ |6 |
| Hong SA |☆ |☆ |☆ |☆ |☆ |☆ |☆ |6 |
| Yu B |☆ |☆ |☆ |☆ |☆ |☆ |☆ |7 |
| Fan JH |☆ |☆ |☆ |☆ |☆ |☆ |☆ |7 |
| Fu Y |☆ |☆ |☆ |☆ |☆ |☆ |☆ |6 |
| Bao SS |☆ |☆ |☆ |☆ |☆ |☆ |☆ |7 |
| Han XY |☆ |☆ |☆ |☆ |☆ |☆ |☆ |6 |
| Xiao L |☆ |☆ |☆ |☆ |☆ |☆ |☆ |7 |
### Table S2. PRISMA 2009 Checklist.

| Section/Topic          | # | Checklist Item                                                                 | Reported on page # |
|------------------------|---|--------------------------------------------------------------------------------|-------------------|
| **TITLE**              |   |                                                                                |                   |
| Title                  | 1 | Identify the report as a systematic review, meta-analysis, or both.            | 1                 |
| **ABSTRACT**           |   |                                                                                |                   |
| Structured summary     | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1                 |
| **INTRODUCTION**       |   |                                                                                |                   |
| Rationale              | 3 | Describe the rationale for the review in the context of what is already known. | 2 - 3             |
| Objectives             | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 2 - 3             |
| **METHODS**            |   |                                                                                |                   |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | No               |
| Eligibility criteria   | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 2 - 3             |
| Information sources    | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 2                 |
| Search                 | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 2                 |
| Study selection        | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 2 - 3             |
| Data collection process| 10| Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 3                 |
| Data items             | 11| List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 2 - 3             |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 3 - 4             |
| Summary measures       | 13| State the principal summary measures (e.g., risk ratio, difference in means).    | 3 - 4             |
| Synthesis of results   | 14| Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis. | 3 - 4             |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 4                 |
| Additional analyses    | 16| Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 4                 |
| **RESULTS**            |   |                                                                                |                   |
| Study selection        | 17| Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | Figure 1          |
| Study characteristics  | 18| For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | Table 1           |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 4 Table 3         |
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. Table 3 Figure 3 & 4 3-4

Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. Table 2 Figure 2 4

Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). 4

Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). 3 - 4

DISCUSSION 24

Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). 4 - 5

Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). 4

Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 4 - 5

FUNDING 27

Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 5

Figure S1. The association of elevated YAP expression with clinicopathological features of GC. Forest plots for the association between elevated YAP expression and (a) gender, or (b) tumor size in GC. Sensitivity analysis for the association between elevated YAP expression and (c) gender, or (d) tumor size in GC.